Accumulation of DnA double-strand breaks (DSBs) is linked to aging and age-related diseases. We recently reported the possible association of DnA DSBs with altered DnA methylation in murine models of kidney disease. However, DSBs and DnA methylation in human kidneys was not adequately investigated. this study was a cross-sectional observational study to evaluate the glomerular DnA DSB marker γH2AX and phosphorylated Ataxia Telangiectasia Mutated (pATM), and the DNA methylation marker 5-methyl cytosine (5mC) by immunostaining, and investigated the association with pathological features and clinical parameters in 29 patients with IgA nephropathy. To evaluate podocyte DSBs, quantitative long-distance pcR of the nephrin gene using laser-microdissected glomerular samples and immunofluorescent double-staining with WT1 and γH2AX were performed. Glomerular γH2AX level was associated with glomerular DnA methylation level in igA nephropathy. podocytopathic features were associated with increased number of WT1(+)γH2AX(+) cells and reduced amount of pcR product of the nephrin gene, which indicate podocyte DnA DSBs. Glomerular γH2AX and 5mC levels were significantly associated with the slope of eGFR decline over one year in IgA nephropathy patients using multiple regression analysis adjusted for age, baseline eGfR, amount of proteinuria at biopsy and immunosuppressive therapy after biopsy. Glomerular γH2AX level was associated with DNA methylation level, both of which may be a good predictor of renal outcome in igA nephropathy.
revised Oxford Classification from 2016 13 . Therefore, evaluations of podocyte DSBs are important to determine whether they are involved in disease progression partially via epigenetic changes. The association of glomerular DNA DSBs and DNA methylation with disease progression has not been shown in IgA nephropathy, although a previous study reported an association between 8-OHdG, an indicator of oxidative DNA damage, and interstitial fibrosis in IgA nephropathy 15 .
This study investigated the association between glomerular γH2AX immunostaining, which are markers of DNA DSBs, and glomerular 5-methyl cytosine (5mC) immunostaining, a marker of DNA methylation. γH2AX, the phosphorylated histone variant of H2AX, plays an important role in the recruitment of DNA repair factors to damaged sites during the initial phase of repair, and it is frequently used as a marker of DNA DSBs 16 . We confirmed glomerular DNA DSBs using immunostaining with phosphorylated ataxia telangiectasia mutated (pATM), activated ATM that phosphorylates H2AX in the response to DNA DSBs. To evaluate podocyte DNA DSBs, the amount of DNA DSBs in the nephrin gene, including the promoter region, was examined by quantitative PCR, as previously described in mice 9, 17 , using laser-microdissected glomerular samples as well as double-immunostaining with podocyte marker WT1 and γH2AX. The PCR product levels reflect DNA DSBs primarily in podocytes because opened chromatin is vulnerable to injury [18] [19] [20] , and chromatin condensation of the nephrin promoter region is opened in podocytes 9 . The present study revealed an association of glomerular DNA DSBs with DNA methylation and eGFR decline over one year in IgA nephropathy patients.
Results participant characteristics.
A total of 29 individuals (17 males and 12 females) aged 45.7 ± 3.0 years were eligible for inclusion in the present study. Table 1 shows the general characteristics of the subjects. The following average clinical values were recorded: eGFR at biopsy was 57.0 ± 4.4 ml/min/1.73 m 2 ; eGFR 1 year after biopsy was 55.7 ± 4.9 ml/min/1.73 m 2 ; the amount of proteinuria at biopsy was 1.76 ± 0.30 g/day; and the amount of proteinuria 1 year after biopsy was 0.55 ± 0.13 g/gCr. Four control samples with normal glomerular findings from the patients with asymptomatic microscopic hematuria or with normal urinalysis were available in this study to compare the levels of DNA DSBs and DNA methylation with IgA nephropathy kidneys. As shown in Table 1 , eGFR at baseline and one year after biopsy were significantly reduced in IgA nephropathy patients compared with the controls. In IgA nephropathy patients, 2, 7, 23, and 11 patients showed mesangial hypercellularity, endocapillary hypercellularity, segmental sclerosis and crescents, respectively, according to the Oxford classification. Considering tubular atrophy and interstitial fibrosis, 6 and 3 patients were classified into T1 and T2, respectively. Podocytopathy was observed in 9 patients. Fifteen patients received immunosuppressive therapy. Seventeen patients exhibited hypertension at biopsy using the criteria described in the Methods section, and 15 patients were treated with angiotensin receptor blocker (ARB).
Association of DnA double-strand breaks with glomerular DnA methylation in patients with igA nephropathy. First, DNA DSB and DNA methylation levels were examined in glomeruli of IgA nephropathy patients and controls. Immunostainings of γH2AX and pATM, DNA DSB markers, and 5-methyl cytosine (5mC), a DNA methylation marker, were observed in the nuclei of glomerular and tubular cells as shown in Fig. 1 . The number of mean γH2AX-positive cells and pATM-positive cells per glomerulus, which indicate DNA DSBs, were significantly increased in patients with IgA nephropathy compared to controls (p = 0.0015 and p = 0.0060, respectively).
To evaluate podocyte DNA DSBs in IgA nephropathy, immunofluorescent double staining with γH2AX and podocyte marker WT1, and a long-distance PCR analysis with samples obtained from serial biopsy slides using laser microdissection were performed. The number of glomerular WT1(+)γH2AX(+)cells, which indicate podocytes with DNA DSBs, was increased in IgA nephropathy compared to controls (p = 0.0024). The numbers of glomerular γH2AX-positive cells was correlated with the number of WT1(+)γH2AX(+) cells (r = 0.3465, p = 0.0482), suggesting that podocyte DNA DSBs were associated with increased glomerular DSBs at least in part. Then, we prepared primer sets in the nephrin genes to quantify DNA DSBs in the region. The amount of PCR products of the nephrin gene adjusted by the total glomerular area was correlated with the mean number of WT1(+)γH2AX(+) cells per glomerulus (r = −0.4244, p = 0.0274).
Next, we investigated the association between DNA DSBs and DNA methylation in 243 glomeruli of IgA nephropathy using γH2AX and 5mC immunostaining by Pearson's correlation coefficient and a univariate regression model. The glomerular γH2AX level was significantly correlated with the 5mC level (r = 0.3372, p < 0.0001) (Fig. 2) . The mean number of γH2AX-positive cells per glomerulus was significantly correlated with the γH2AX level (r = 0.4983, p = 0.0059), and also associated with the 5mC level (r = 0.3738, p = 0.0458).
Association of DnA double-strand breaks and DnA methylation with the pathological features of igA nephropathy.
We examined the association of glomerular γH2AX and 5mC levels and long-distance PCR products of the nephrin gene with the pathological features of IgA nephropathy. The glomerular γH2AX level was marginally associated with segmental sclerosis in the analysis of each glomerulus (p = 0.07). No significant association was observed with glomerular γH2AX staining of a specific glomerular area, such as vascular or tubular poles. Presence of podocytopathy was significantly associated with the long-PCR product of the nephrin gene (p = 0.0413) as well as the mean number of WT1(+)γH2AX(+) cells per glomerulus (p = 0.0038) ( Fig. 3A,B ).
Association of DnA double-strand breaks and DnA methylation with the eGfR decline in patients with igA nephropathy.
The association between eGFR decline over one year after biopsy and the mean glomerular γH2AX and 5mC levels were investigated using a multiple linear regression model adjusted for age, eGFR and urinary protein level at biopsy ( Table 2) . Glomerular γH2AX and 5mC levels were significantly associated with increased slope of eGFR decline over one year independently of age, eGFR and amount of proteinuria at biopsy (r 2 = 0.41, p = 0.0068 and r 2 = 0.52, p = 0.0005, respectively). In addition, the glomerular γH2AX and 5mC levels were also significantly associated with the slope of eGFR decline in multiple regression analysis adjusted for age, eGFR amount of proteinuria at biopsy and presence of immunosuppressive therapy or ARB treatment (γH2AX: r 2 = 0.43, p = 0.0060 and r 2 = 0.41, p = 0.0091, 5mC: r 2 = 0.60, p = 0.0001 and r 2 = 0.55, p = 0.0005, respectively). We confirmed that the numbers of γH2AX-positive cells or pATM-positive cells were correlated with the slope of eGFR decline over one year (r = −0.7116, p < 0.0001; r = −0.4243, p = 0.0307). Multivariate regression analysis showed the significant association of the number of γH2AX-positive cells with the slope of eGFR decline after adjustment by age, baseline eGFR and proteinuria (r 2 = 0.58, p = 0.00014). It was also significant after adjustment by age, sex, baseline eGFR, proteinuria and presence of hypertension (r 2 = 0.62, p = 0.00009).
Discussion
This study demonstrated the following results in patients with IgA nephropathy: (1) correlation between glomerular DNA DSBs and DNA methylation, (2) association of podocyte DNA DSBs with podocytopathic features and (3) association of glomerular γH2AX or 5mC levels with the slope of eGFR decline over one year.
We previously reported that altered DNA methylation in podocytes is involved in the pathogenesis of chronic kidney disease 21, 22 , and recently suggested that impaired DNA DSB repair is associated with altered DNA methylation in podocytes 9 . Emerging evidence indicates that epigenetic mechanisms may contribute to kidney disease progression, and recent studies have successfully indicated the importance of kidney DNA methylation on renal function in humans 23, 24 , although the association of DNA DSBs with DNA methylation and renal function in human kidneys has not been investigated. The present study demonstrated that glomerular DNA DSBs were positively correlated with glomerular DNA methylation in each glomerulus, which is in agreement with our previous results in murine models. A recent in vitro study suggested that the repair of DSBs by nonhomologous end joining (NHEJ), which is the dominant pathway of DSB repair in eukaryotes, facilitated modification of the methylation landscape in repaired genes 8 . The authors indicated that methylation patterns differed between post-repair populations and cells with uncut DNA, and that NHEJ repair could cause either hypomethylation or hypermethylation depending on the damaged region. These results suggest that the repair process itself, even if completed, alters DNA methylation. Further basic investigations of the precise mechanism of altered DNA methylation associated with DSBs and their repair may be necessary to explain the significance of altered glomerular DNA methylation.
As shown in Table 2 , every 10% increase in total glomerular area according to γH2AX-positive staining or 5mC-positive staining contributed to a decrease in eGFR over one year of approximately 30 ml/min/1.73 m 2 or 40 ml/min/1.73 m 2 , respectively. These effects were observed independently of known factors related to renal outcome, including baseline eGFR, proteinuria, and treatment with immunosuppressive agents or ARBs. Therefore, these DNA markers in glomerular cells may be good predictors of renal outcome and become novel therapeutic targets with pathways different from those of existing immunosuppressive therapies and ARB treatment. Recent reports have shown that podocyte hypertrophy or sclerosis at the tubular pole, which are typical features associated with podocytopathies, are correlated with more proteinuria at presentation and a more rapid decline in renal function 14, 25 . Therefore, we investigated podocyte DSBs using double immunostaining with WT1 and γH2AX antibody and quantitative long-distance PCR method 17 . Podocyte DNA DSBs were evaluated using long-distance PCR method in our previous study in mice 9 , and we applied this method to human samples in the present study. Podocyte DSBs evaluated by both methods were significantly correlated with podocytopathic features. Notably, podocyte DSBs were associated with the mean glomerular γH2AX levels, which suggests that the increased amount DNA DSBs in podocytes contributed to the increased amount of glomerular DNA DSBs at least in part. Further study for evaluation of DNA DSBs in other types of glomerular cells, such as endothelial cells and mesangial cells, may be necessary. The involvement of the factor mesangial hypercellularity (Oxford M0 and M1) or endothelial hypercellularity (Oxford E0 and E1) in multiple regression analysis may be useful for evaluating the contribution of DNA DSBs in proliferated mesangial cells or endothelial cells, but the M1 and E1 populations were very small in this study. www.nature.com/scientificreports www.nature.com/scientificreports/ Segmental sclerosis in IgA nephropathy may result from segmental necrotizing or endocapillary inflammatory lesions, or a response to podocyte injury analogous to primary focal segmental glomerulosclerosis (FSGS) 13 . Therefore, segmental sclerosis in advanced IgA nephropathy may reflect adaptive FSGS lesions in part, which may be related to the accumulation of DNA damage, represented by increased γH2AX levels. However, Oxford classification S1 was not significantly associated with the mean glomerular γH2AX level or eGFR decline after adjustment for age, baseline eGFR and proteinuria, likely because Oxford classification S1 indicates the presence of segmental sclerosis or adhesion without quantitative evaluation of the lesions, and it does not reflect the amount of DNA DSBs in the total glomeruli.
The present study has some limitations. First, this study did not have data from long periods of time after kidney biopsy. Second, the number of subjects was small for the assessments of the involvement of clinical parameters, such as the therapy type and responsiveness to therapies, and the association of podocyte DSBs with renal outcomes. Further studies are necessary to determine the association of glomerular and podocyte DNA DSBs with renal outcomes in larger populations of patients with IgA nephropathy for longer observational periods. Third, which types of cells contributed to the increased amount of DNA DSBs in glomeruli was not clarified, but increased amounts of podocyte DSBs was associated with increased amounts of glomerular DNA DSBs, at least in part. Finally, this study focused on IgA nephropathy. However, it is necessary to investigate the importance of DNA DSBs and the association of DNA DSBs with DNA methylation and renal outcomes in other types of nephropathy.
To our knowledge, this study is the first study to demonstrate the possible association of glomerular DNA DSBs with a decline in kidney functions and glomerular DNA methylation in IgA nephropathy patients, despite these limitations. Focusing on the relationship between DNA DSBs and DNA methylation may lead us to novel approaches to understand the pathogenesis of and predict renal outcomes in chronic kidney disease patients.
Methods

Study population.
A total of 55 individuals were diagnosed with IgA nephropathy based on kidney biopsies performed from January 1, 2015, to December 31, 2017, in Keio University Hospital. IgA nephropathy was defined immunohistologically using dominant or codominant glomerular deposits of IgA 26 . Five patients changed hospitals after biopsy or were lost to follow-up. We excluded individuals without informed consent, individuals www.nature.com/scientificreports www.nature.com/scientificreports/ without essential data and individuals with less than two glomeruli without global sclerosis in the biopsy samples. Patients who had IgA vasculitis nephritis or secondary IgA nephropathy were also excluded. Twenty-nine IgA nephropathy patients were ultimately included in this study. None of the patients was receiving immunosuppressive therapies at the time of biopsy. Four control samples with normal glomerular findings were obtained during the study period, from January 1, 2015, to December 31, 2017 from the patients with asymptomatic microscopic hematuria or with normal urinalysis when kidney biopsy was performed. clinical evaluation and laboratory measurements. Blood pressure was measured on the right upper arm after subjects had rested at least 5 min in a sitting position in the hospital using an automatic BP-900 device with a combination of the Korotkoff sounds method and the oscillometric technique (TANITA Co. Tokyo, Japan). Blood samples were collected and immediately analyzed using an automated clinical chemical analyzer. Urinary protein excretion at biopsy was measured using 24-hour urine collection one day prior to kidney biopsy during the hospital stay. Urinary protein excretion 1 year after biopsy was calculated from the urinary protein concentration/urinary creatinine concentration at the time of the outpatient visit.
Definitions. eGFR was calculated using the following equation: eGFR (ml/min/1.73 m 2 ) = 194 × serum creatinine (−1.094) × age (−0.287) × 0.739 (if female) 27 . The slope of eGFR decline over one year was calculated by standard linear models using the data of eGFR at biopsy, 6 months and one year after biopsy as reported previously 28 . Hypertension was defined as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg or if the patient indicated the use of antihypertensive drugs. Diabetes at biopsy was defined in accordance with the guidelines of the American Diabetes Association as a fasting glucose concentration ≥126 mg/dl, HbA1c level ≥6.5% 29 or the use of antihyperglycemic drugs. Two expert pathologists performed pathological diagnoses and scoring according to the Oxford Classification.
immunohistochemistry. The kidney samples were fixed in 10% formalin and embedded in paraffin blocks.
Five-micron-thick serial sections were used for immunohistochemistry and laser microdissection. The paraffin sections were stained with periodic acid-Schiff (PAS) or γH2AX (NB100-384, Novus Biologicals, Colorado, USA) and 5-methyl cytosine (sc-56615, Santa Cruz Biotechnology, Texas, USA) antibodies followed by incubation with a peroxidase-conjugated secondary antibody and 3,3-diaminobenzidine tetrahydrochloride (DAB) staining 9 . Hematoxylin was used as a nuclear counterstain. Immunofluorescent staining was performed as previously described 21, 30 using γH2AX, WT1 (sc-7385, Santa Cruz Biotechnology, Texas, USA) and phosphorylated Ataxia Telangiectasia Mutated (pATM) (200-301-400, Rockland, PA, USA) antibodies. Images of all glomeruli without global sclerosis in the biopsy sample were acquired via microscopic examination (400x magnification), and the glomerular area was quantified using color channel analysis and pixel counting using Photoshop CC 2018 software (Adobe) and was divided by the area of the glomerular tuft, as previously described 21 .
Laser microdissection and long distance-pcR method. Laser microdissection was performed using paraffin sections by a PALM MicroBeam IP 230 V Z microscope for laser oressure catapulting (P.A.L.M. Microlaser Technologies, Bernried, Germany) as described previously 31, 32 . DNA was extracted from laser-microdissected glomerular samples using NucleoSpin Tissue (Takara Bio, Shiga, Japan). The quantitative long-distance PCR method for detecting DNA damage is based on the assumption that DNA with fewer DSB lesions will amplify to a greater extent than more damaged DNA if equal amounts of DNA from different samples are amplified under identical conditions, as described previously in mice 17, 33 . We created primers to amplify an approximately 10000-bp section of the nephrin promoter region (Forward 5′-CTGCCATCAGCAACTCTCCA, Reverse 5′-CTCTGCCTCTGTTGTGCTGA, product length of 10303 bp), and we calculated the relative amount of the PCR products divided by the total glomerular area.
Statistics.
Pearson's test was used for univariable analyses for continues variables, which are expressed as the means ± standard deviations (SD). Mann-Whitney test was used for the analysis of patients with IgA nephropathy compared to the controls. Multiple linear regression analysis was performed to evaluate the association with eGFR decline over one year, adjusted for age, eGFR and urinary protein excretion at biopsy. We confirmed each variance inflation factor (VIF) was less than 10. The presence of immunosuppressive therapy, ARB treatment, sex or presence of hypertension was also included as an adjusted factor. The significance level for all tests in this study was two-sided 5%. All statistical analyses were performed using JMP version 13 (SAS Institute Inc., Cary, NC, USA). Study approval. The Ethics Committee of Keio University School of Medicine approved the present study (approval number: 20180159). Written informed consent was received from participants prior to inclusion in the study. Participants were identified using a number, not their name. It was conducted in adherence with the Declaration of Helsinki. All methods were carried out in accordance with the institutional guidelines of the ethics committee at Keio University (Tokyo, Japan).
